General Information of Drug (ID: DMJ432G)

Drug Name
GMI-1070 Drug Info
Synonyms
GMI-1010; GMI-1011; GMI-1040 series; GMI-1077; Glyosin, GlycoMimetics; Heterobifunctional glycomimetic pan-selectin inhibitors (smallmolecule therapeutic), GlycoMimetics; Selectin inhibitors (asthma/sickle cell anemia/hematological neoplasm), GlycoMimetics
Indication
Disease Entry ICD 11 Status REF
Asthma CA23 Phase 3 [1]
Vaso-occlusive crisis BE2Y Phase 3 [2]
Cross-matching ID
PubChem CID
44232546
CAS Number
CAS 927881-99-0
TTD Drug ID
DMJ432G

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug(s) Targeting P-selectin (SELP)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Crizanlizumab DMAHOVJ Vaso-occlusive crisis BE2Y Approved [4]
Inclacumab DMXV94M Sickle-cell disorder 3A51 Phase 3 [5]
CY-1503 DML906E Hypertension BA00-BA04 Phase 2/3 [6]
BAICALEIN DM4C7E6 Influenza virus infection 1E30-1E32 Phase 2 [7]
SelG1 DMTQ2K0 Vaso-occlusive crisis BE2Y Phase 2 [8]
RPSGL-Ig DM0BFJ5 Delayed graft function 4B24.0 Phase 2 [9]
PSI-697 DM75FWO Atherosclerosis BD40 Phase 1 [10]
CDP-850 DMWHQM3 Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 2 [11]
CY-1787 DMWY2NT Allergy 4A80-4A85 Discontinued in Phase 1 [12]
PURPUROGALLIN DM63O4F N. A. N. A. Terminated [7]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting L-selectin (SELL)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BAICALEIN DM4C7E6 Influenza virus infection 1E30-1E32 Phase 2 [7]
PURPUROGALLIN DM63O4F N. A. N. A. Terminated [7]
Hu Dreg 55 DMK1VHF Psoriasis vulgaris EA90 Terminated [13]
2,3,4-trihydroxybenzoic acid DMWHK35 Discovery agent N.A. Investigative [7]
LD201t1 DMC5XQ6 Inflammation 1A00-CA43.1 Investigative [14]
Drug(s) Targeting E-selectin (SELE)
Drug Name Drug ID Indication ICD 11 Highest Status REF
GMI-1271 DMDTGWQ Acute myeloid leukaemia 2A60 Phase 3 [13]
CY-1503 DML906E Hypertension BA00-BA04 Phase 2/3 [6]
Bimosiamose DM0TH9A Atopic dermatitis EA80 Phase 2a [15]
GMI-1359 DML1KSA Breast cancer 2C60-2C65 Phase 1 [16]
PF-07209326 DM7YRAL Sickle-cell disorder 3A51 Phase 1 [17]
GI-270384X DM3KN2Q Inflammatory bowel disease DD72 Terminated [18]
Fucose DMAHMSV N. A. N. A. Investigative [19]
O-Sialic Acid DMCAR7B Discovery agent N.A. Investigative [20]
Efomycine M DMOKX76 Discovery agent N.A. Investigative [21]
1na DM0A1YI Discovery agent N.A. Investigative [19]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
E-selectin (SELE) TTAU4D6 LYAM2_HUMAN Inhibitor [3]
L-selectin (SELL) TT2IYXF LYAM1_HUMAN Inhibitor [3]
P-selectin (SELP) TTE5VG0 LYAM3_HUMAN Inhibitor [3]
Selectin (SEL) TTBGONL NOUNIPROTAC Antagonist [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8307).
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Deal watch: Pfizer deal for selectin inhibitor highlights potential of glycomimetic drugs. Nat Rev Drug Discov. 2011 Dec 1;10(12):890.
4 Crizanlizumab: First Approval. Drugs. 2020 Jan;80(1):79-84.
5 Analytical comparability demonstrated for an IgG4 molecule, inclacumab, following transfer of manufacturing responsibility from Roche to Global Blood Therapeutics. Expert Opin Biol Ther. 2022 Nov;22(11):1417-1428.
6 Adjunctive selectin blockade successfully reduces infarct size beyond thrombolysis in the electrolytic canine coronary artery model. Circulation. 1995 Aug 1;92(3):492-9.
7 Rational design of novel, potent small molecule pan-selectin antagonists. J Med Chem. 2007 Mar 22;50(6):1101-15.
8 Clinical pipeline report, company report or official report of Selexys Pharmaceuticals (2011).
9 rPSGL-1-Ig, a recombinant PSGL-1-Ig fusion protein, ameliorates LPS-induced acute lung injury in mice by inhibiting neutrophil migration. Cell Mol Biol (Noisy-le-grand). 2015 Feb 28;61(1):1-6.
10 Effect of PSI-697, a novel P-selectin inhibitor, on platelet-monocyte aggregate formation in humans. J Am Heart Assoc. 2013 Jan 28;2(1):e006007.
11 WO patent application no. 2001,0276,21, Competitive inhibition elisa for antibody detection.
12 Administration of an antibody to E-selectin in patients with septic shock. Crit Care Med. 1996 Feb;24(2):229-33.
13 Clinical pipeline report, company report or official report of glycomimetics.
14 Therapeutic applications of aptamers. Expert Opin Investig Drugs. 2008 Jan;17(1):43-60.
15 Effects of the pan-selectin antagonist bimosiamose (TBC1269) in experimental human endotoxemia. Shock. 2008 Apr;29(4):475-82.
16 Clinical pipeline report, company report or official report of GlycoMimetics.
17 ClinicalTrials.gov (NCT04255875) A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED EVALUATION OF SINGLE DOSES OF PF-07209326 IN HEALTHY PARTICIPANTS (SAFETY, TOLERABILITY, AND PHARMACOKINETICS [PK]) FOLLOWED BY AN OPEN LABEL, REPEAT DOSE EVALUATION IN SICKLE CELL DISEASE PARTICIPANTS (SAFETY, TOLERABILITY, PK AND EFFICACY). U.S.National Institutes of Health.
18 Inhibition of endothelial cell adhesion molecule expression improves colonic hyperalgaesia. Neurogastroenterol Motil. 2009 Feb;21(2):189-96.
19 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
20 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
21 Interfering with leukocyte rolling--a promising therapeutic approach in inflammatory skin disorders Trends Pharmacol Sci. 2003 Feb;24(2):49-52.